stockrowRockwell Medical, Inc.
RMTIHealthcare Drug Manufacturers Specialty & Generic
Rockwell Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.3 million, down 31.8% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- +32.0%
- Free cash flow
- −12.9%
- Total debt
- −1.73%
Quarter to June 2026, against a year earlier
Follow RMTI
Alert me
Rockwell Medical, Inc. (RMTI) EV/Sales
As of 6 November 2026, Rockwell Medical, Inc. (RMTI) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from 0.0× (July 2022) to 89.7× (January 2015); the current reading is higher than 8% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.8× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.3× | (49.00%) |
| FY2024 | 0.6× | (19.76%) |
| FY2023 | 0.7× | 1,021.22% |
| FY2022 | 0.1× | (89.47%) |
| FY2021 | 0.6× | (7.67%) |
| FY2020 | 0.6× | (69.02%) |
| FY2019 | 2.1× | 33.75% |
| FY2018 | 1.5× | (66.85%) |
| FY2017 | 4.7× | (11.46%) |
| FY2016 | 5.3× | (35.84%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.1× | (70.76%) |
| Mar 2026 | 0.3× | 5.68% |
| Dec 2025 | 0.3× | (37.14%) |
| Sep 2025 | 0.5× | 56.23% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. compare | −24.2× |
| ZYBT Zhengye Biotechnology Holding Limited compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| RMTI Rockwell Medical, Inc. | 0.2× |
| INCR InterCure Ltd. compare | 0.6× |
| SCYX SCYNEXIS, Inc. compare | 0.6× |
| CPHI China Pharma Holdings, Inc. compare | 6.7× |
| TXMD TherapeuticsMD, Inc. compare | 84.5× |
| Drug Manufacturers Specialty & Generic industry median | 2.8× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)